Alembic Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Fri Mar 20 2026

Alembic Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Alembic was listed on the National Stock Exchange (NSE) on 22-Sep-1999. Alembic share has its face value of 2 per share, and its NSE symbol is ALEMBICLTD. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

Alembic Q4 Results 2026 Preview

Alembic Q4 FY26 revenue is expected to be around Strong Growth Expected, representing a 16-22% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 18-25% YoY.
EBITDA to rise 17-23%.
Alembic is expected to show Strong Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Alembic Share Performance

Over the past six months, Alembic share price has Up by 30% to 79.67.
Moreover, over the past year, the stock has Up by 52%
Despite this weak short-term performance, Alembic stock has delivered a financially sound 260% return over the past 5 years.
As of today, 20-03-2026, the Alembic share price is trading at 79.67 per share.

Key Factors to Watch for Alembic Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Alembic

Alembic is a pharmaceutical company engaged in the manufacturing and marketing of generic formulations and active pharmaceutical ingredients, serving both domestic and international markets. It is known for a diversified product portfolio and a strong focus on research and development.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Alembic is gear up to announce its Q4 FY26 results. Analysts expect 16-22% revenue growth, a 18-25% rise in PAT, and a 17-23% rise in EBITDA. Alembic focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Alembic Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.